Loading…
← CockpitCompetitor Analysis › 300439.SZ MedicalSystem Biotechnology Co., Ltd. Class AOpen in the cockpit ↗

MedicalSystem Biotechnology Co., Ltd. Class A300439.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties
Momentum leader 83
Mkt cap
$518M
US dollars, full cap
Free float
90%
of shares outstanding
$/day
$10.0M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-0.7 pp
WACC 6.9%
Hurdle
+14 pp
Req g minus delivered
Close · CNYCN¥9.06
1D-2.9%
1W-6.9%
1M-5.0%
3M-2.3%
6M-9.5%
YTD-8.0%
1Y-13.8%
ATR %4.4%
52w lowhigh18.4% off high

What MedicalSystem Biotechnology does

Employees: 1,936

MedicalSystem Biotechnology at a glance

Size MedicalSystem Biotechnology (300439.SZ) is a China Health Care company (Medical Specialties) with a market value of $518M, the 3612th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥9.06 on 18 Nov 2026.

Performance Over six months the shares fell 9.5%, against -20.6% for the median peer and -20.0% for the China market (cap-weighted) — 7th highest of 21 in its peer set.

Growth Revenue grew 14.4% over the last twelve months (peer median +3.9%); the operating margin is 2.2% (peer median 2.4%).

Valuation It trades at 1.5× enterprise value to sales against a peer median of 4.6× (4th cheapest of 19).

Price implies For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is -8%, so the hurdle is +14 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 0.7 points below its cost of capital (6.9% WACC).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026300439.SZ 91Peer median 82
Six months, rebased to 100: MedicalSystem Biotechnology against the median of its 20 peers (local-currency closes).

MedicalSystem Biotechnology financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.68BCN¥1.53BCN¥1.74BCN¥1.88BCN¥2.48B
Revenue growth—-12%-7%-24%—
Gross profitCN¥683MCN¥496MCN¥718MCN¥767MCN¥892M
EBITDAn/aCN¥180MCN¥456MCN¥437MCN¥415M
Net incomeCN¥101MCN¥63.2MCN¥258MCN¥257MCN¥199M
Free cash flowCN¥30.4MCN¥96.4M-CN¥18.7MCN¥383MCN¥270M
Capital expenditureCN¥153MCN¥191MCN¥421MCN¥280MCN¥303M
Total debtCN¥112MCN¥83.0MCN¥89.9MCN¥108MCN¥352M

Quarterly statements and history in the cockpit →

MedicalSystem Biotechnology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%NNNN3006397979AVRRCEL688075MYGNZJYL688298688580605369MEDX300869603520002932603122CEVI300439.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. MedicalSystem Biotechnology is the large dot.

Fundamentals: revenue growth against valuation

-20%-10%0%+10%+20%0×50×100×3006397979AVRRCEL688075MYGNZJYL688298688580300869301033603122CEVI300439.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. MedicalSystem Biotechnology is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%+60%0%25%50%300639688075688580605369MEDX300869688606301033300246CEVI300439.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. MedicalSystem Biotechnology is the large dot.

MedicalSystem Biotechnology competitors and peer comparison

How MedicalSystem Biotechnology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

MedicalSystem Biotechnology against its 20 peers (data as of 18 Nov 2026)
Measure300439.SZPeer medianRank in peer set
1-month return-5.0%-6.7%10th highest of 21
6-month return-9.5%-20.6%7th highest of 21
Distance from 52-week high-18.4%-41.7%5th highest of 21
Revenue growth (TTM)+14.4%+3.9%4th highest of 21
Operating margin2.2%2.4%11th highest of 21
EV / Sales1.5×4.6×4th cheapest of 19
Growth the price implies (Req g, 7 yrs)6.0%8.7%5th least demanding of 11
Growth delivered (Del g)-7.7%-0.1%4th lowest of 11
Hurdle (Req g minus delivered)+13.8 pp+8.7 pp5th most demanding of 11
ROIC minus cost of capital-0.7 pp-2.2 pp7th highest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
MedicalSystem Biotechnology 300439.SZChina$518M-9%+14%2%1.5×6.0%-7.7%
Anbio Biotechnology NNNNUnited States$518M-89%+10%67%n/an/an/a
Guangdong Hybribio Biotech 300639.SZChina$511M-18%-7%4%3.9×0.4%-13.2%
Shofu 7979.TJapan$510M+32%+9%14%1.6×n/an/a
Anteris Technologies Global AVRUnited States$508M-40%+9%-4,880%125.0×n/an/a
AVITA Medical RCELUnited States$529M+290%+17%-34%6.7×n/an/a
Assure Tech (Hangzhou) 688075.SSChina$508M-27%-9%-8%5.4×30.8%-18.6%
Myriad Genetics MYGNUnited States$530M+45%-3%-13%0.8×n/an/a
Jin Medical International ZJYLUnited States$532M+47%-14%2%26.5×n/an/a
Zhejiang Orient Gene Biotech 688298.SSChina$500M-27%+18%-60%1.6×n/an/a
Nanjing Vishee Medical Technology 688580.SSChina$499M-43%+7%24%5.3×20.1%+4.2%
Zhejiang Gongdong Medical Technology 605369.SSChina$542M-21%+6%9%2.6×10.2%+6.5%
medmix MEDX.SWSwitzerland$494M+11%-7%6%1.4×4.5%+5.0%
Contec Medical Systems 300869.SZChina$547M-26%-2%-16%5.5×15.0%-19.8%
Zhejiang Starry Pharmaceutical 603520.SSChina$491M-44%+9%3%2.2×n/an/a
Wuhan Easy Diagnosis Biomedicine 002932.SZChina$485M-14%-9%-51%n/an/an/a
Hangzhou Alltest Biotech 688606.SSChina$484M-20%0%13%1.3×-6.5%-4.3%
Medprin Regenerative Medical Technologies 301033.SZChina$482M-14%+23%31%7.0×4.3%+24.4%
Guangdong Biolight Meditech 300246.SZChina$478M-35%+7%-8%3.1×55.3%-4.7%
Cowealth Medical China 603122.SSChina$562M-34%-18%-5%5.9×n/an/a
CellaVision CEVI.STSweden$477M+64%+2%23%6.1×7.1%+10.0%

Questions

Which companies are MedicalSystem Biotechnology's closest peers?
The cockpit's peer set: Anbio Biotechnology (NNNN), Guangdong Hybribio Biotech (300639.SZ), Shofu (7979.T), Anteris Technologies Global (AVR), AVITA Medical (RCEL), Assure Tech (Hangzhou) (688075.SS), Myriad Genetics (MYGN), Jin Medical International (ZJYL).
Is MedicalSystem Biotechnology expensive compared with its peers?
On ev / sales it trades at 1.5× against a peer median of 4.6×, 4th cheapest of 19 in its peer set. For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is -8%, so the hurdle is +14 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has MedicalSystem Biotechnology stock performed?
Over six months to 18 Nov 2026 the shares returned -9.5% against -20.6% for the median peer; over one year -13.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.